Terms: = Breast cancer AND HLF, Q16534, 3131, ENSG00000108924
33 results:
1. A Prognostic Model of Genetic Markers for Triple-Negative breast cancer Based on Machine Learning and Bioinformatics Analysis.
Guan H; Su Y; Guo W; Chen C; Xie X; Lv X
Stud Health Technol Inform; 2023 Nov; 308():303-312. PubMed ID: 38007754
[TBL] [Abstract] [Full Text] [Related]
2. hlf promotes ovarian cancer progression and chemoresistance via regulating Hippo signaling pathway.
Han T; Chen T; Chen L; Li K; Xiang D; Dou L; Li H; Gu Y
Cell Death Dis; 2023 Sep; 14(9):606. PubMed ID: 37709768
[TBL] [Abstract] [Full Text] [Related]
3. Concurrent Validity of the IOPI and Tongueometer Orofacial Strength Measurement Devices.
Curtis JA; Mocchetti V; Rameau A
Laryngoscope; 2023 Nov; 133(11):3123-3131. PubMed ID: 37249206
[TBL] [Abstract] [Full Text] [Related]
4. Selectively attacking tumor cells of Ru/Ir-arene complexes based on meclofenamic acid
Huang Y; Lv M; Guo B; Hu G; Qian Y; Su Z; Xue X; Liu HK
Dalton Trans; 2023 May; 52(20):6922-6933. PubMed ID: 37158602
[TBL] [Abstract] [Full Text] [Related]
5. hlf regulates ferroptosis, development and chemoresistance of triple-negative breast cancer by activating tumor cell-macrophage crosstalk.
Li H; Yang P; Wang J; Zhang J; Ma Q; Jiang Y; Wu Y; Han T; Xiang D
J Hematol Oncol; 2022 Jan; 15(1):2. PubMed ID: 34991659
[TBL] [Abstract] [Full Text] [Related]
6. Glycaemic index, glycaemic load and cancer risk: results from the prospective NutriNet-Santé cohort.
Debras C; Chazelas E; Srour B; Julia C; Kesse-Guyot E; Zelek L; Agaësse C; Druesne-Pecollo N; Andreeva VA; Galan P; Hercberg S; Latino-Martel P; Deschasaux-Tanguy M; Touvier M
Int J Epidemiol; 2022 Feb; 51(1):250-264. PubMed ID: 34491326
[TBL] [Abstract] [Full Text] [Related]
7. The role of unenhanced phase of the liver in the scanning protocol of metastatic breast cancer: implications for sensitivity, response evaluation and size measurement.
Arenas-Jiménez JJ; García-Garrigós E; Planells-Alduvín MC
Radiol Oncol; 2021 Nov; 55(4):418-425. PubMed ID: 34144639
[TBL] [Abstract] [Full Text] [Related]
8. In vitro modeling of solid tumor interactions with perfused blood vessels.
Kwak TJ; Lee E
Sci Rep; 2020 Nov; 10(1):20142. PubMed ID: 33214583
[TBL] [Abstract] [Full Text] [Related]
9. Evaluation of the 8th edition of the American joint committee on cancer's pathological staging system in prognosis assessment and treatment decision making for stage T1-2N1 breast cancer after mastectomy.
Wu SG; Wang J; Lian CL; Lei J; Hua L; Lin Q; Chen YX; He ZY
Breast; 2020 Jun; 51():2-10. PubMed ID: 32172191
[TBL] [Abstract] [Full Text] [Related]
10. Influence of socioeconomic status on immediate breast reconstruction rate, patient information and involvement in surgical decision-making.
Frisell A; Lagergren J; Halle M; de Boniface J
BJS Open; 2020 Apr; 4(2):232-240. PubMed ID: 32003544
[TBL] [Abstract] [Full Text] [Related]
11. The Relationship between Pre-miR-3131 3-bp Insertion/Deletion Polymorphism and Susceptibility and Clinicopathological Characteristics of Patients with breast cancer.
Azizi M; Rahimi N; Bahari G; Hashemi SM; Hashemi M
Microrna; 2020; 9(3):216-223. PubMed ID: 31490768
[TBL] [Abstract] [Full Text] [Related]
12. Oncofetal hlf transactivates c-Jun to promote hepatocellular carcinoma development and sorafenib resistance.
Xiang DM; Sun W; Zhou T; Zhang C; Cheng Z; Li SC; Jiang W; Wang R; Fu G; Cui X; Hou G; Jin GZ; Li H; Hou C; Liu H; Wang H; Ding J
Gut; 2019 Oct; 68(10):1858-1871. PubMed ID: 31118247
[TBL] [Abstract] [Full Text] [Related]
13. A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer.
Criscitiello C; Bayar MA; Curigliano G; Symmans FW; Desmedt C; Bonnefoi H; Sinn B; Pruneri G; Vicier C; Pierga JY; Denkert C; Loibl S; Sotiriou C; Michiels S; André F
Ann Oncol; 2018 Jan; 29(1):162-169. PubMed ID: 29077781
[TBL] [Abstract] [Full Text] [Related]
14. Anticancer activities of bovine and human lactoferricin-derived peptides.
Arias M; Hilchie AL; Haney EF; Bolscher JG; Hyndman ME; Hancock RE; Vogel HJ
Biochem Cell Biol; 2017 Feb; 95(1):91-98. PubMed ID: 28165293
[TBL] [Abstract] [Full Text] [Related]
15. Poly (ADP-ribose) polymerase inhibitors selectively induce cytotoxicity in TCF3-hlf-positive leukemic cells.
Piao J; Takai S; Kamiya T; Inukai T; Sugita K; Ohyashiki K; Delia D; Masutani M; Mizutani S; Takagi M
Cancer Lett; 2017 Feb; 386():131-140. PubMed ID: 27894958
[TBL] [Abstract] [Full Text] [Related]
16. Live Cell MicroRNA Imaging Using Exonuclease III-Aided Recycling Amplification Based on Aggregation-Induced Emission Luminogens.
Min X; Zhang M; Huang F; Lou X; Xia F
ACS Appl Mater Interfaces; 2016 Apr; 8(14):8998-9003. PubMed ID: 27011025
[TBL] [Abstract] [Full Text] [Related]
17. Evaluation of Human Epidermal Growth Factor Receptor 2 (HER2) Gene Status in Human breast cancer Formalin-Fixed Paraffin-Embedded (FFPE) Tissue Specimens by Fluorescence In Situ Hybridization (FISH).
Hwang HC; Gown AM
Methods Mol Biol; 2016; 1406():61-70. PubMed ID: 26820945
[TBL] [Abstract] [Full Text] [Related]
18. Risk-benefit profiles of women using tamoxifen for chemoprevention.
Nichols HB; DeRoo LA; Scharf DR; Sandler DP
J Natl Cancer Inst; 2015 Jan; 107(1):354. PubMed ID: 25475563
[TBL] [Abstract] [Full Text] [Related]
19. Detection and clinical relevance of hematogenous tumor cell dissemination in patients with ductal carcinoma in situ.
Banys M; Hahn M; Gruber I; Krawczyk N; Wallwiener M; Hartkopf A; Taran FA; Röhm C; Kurth R; Becker S; Solomayer EF; Wallwiener D; Staebler A; Fehm T
Breast Cancer Res Treat; 2014 Apr; 144(3):531-8. PubMed ID: 24590774
[TBL] [Abstract] [Full Text] [Related]
20. Delta-lactoferrin, an intracellular lactoferrin isoform that acts as a transcription factor.
Mariller C; Hardivillé S; Hoedt E; Huvent I; Pina-Canseco S; Pierce A
Biochem Cell Biol; 2012 Jun; 90(3):307-19. PubMed ID: 22320386
[TBL] [Abstract] [Full Text] [Related]
[Next]
